Hospital Acquired Pneumonia Drugs

Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market (Tedizolid Phosphate, Ceftolozane/Tazobactam, Ceftazidime/Avibactam, Amikacin Inhale, Plazomicin, and Synflorix) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020

  • Rep Id : TMRGL1881
  • Published On : Sep 2014
  • No. of Pages : 74
  • Category : Pharmaceutical

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Secondary Research
      1.3.2 Primary Research
1.4 List of Abbreviations
1.5 Assumptions
 
Chapter 2 Executive Summary
2.1.1 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
 
Chapter 3 Market overview
3.1 Introduction
      3.1.1 Types of Nosocomial Pneumonia
               3.1.1.1 Bacterial pneumonia
               3.1.1.2 Viral pneumonia
      3.1.2 Epidemiology of hospital acquired pneumonia
      3.1.3 Diagnosis of hospital acquired pneumonia
      3.1.4 Treatment of hospital acquired pneumonia
3.2 Market Dynamics
      3.2.1 Market Drivers
              3.2.1.1 Rising drug resistance among infectious microorganisms increasing chances of hospital acquired infections
              3.2.1.2 Inefficient sterilization and unhygienic conditions in low and middle income countries increasing prevalence of hospital acquired infections
                         3.2.1.2.1 Prevalence of hospital acquired infections in developed and developing countries
      3.2.2 Market Restraints
              3.2.2.1 Government scrutinizing hospital policies to curb hospital-acquired infections
      3.2.3 Market Opportunities
              3.2.3.1 Promising future for vaccines in the nosocomial pneumonia market
              3.2.3.2 Potential for research in vaccine development for causative agents other than S. pneumonia
3.3 Event Impact Analysis
      3.3.1 Event Impact Analysis: Hospital Acquired Pneumonia Market
3.4 Value Chain Analysis
      3.4.1 Value Chain Analysis
3.5 Porter’s Five Forces Analysis for the Global Hospital Acquired Pneumonia Drugs Market
      3.5.1 Bargaining Power of Suppliers
      3.5.2 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
      3.5.3 Bargaining Power of Buyers
      3.5.4 Threat of Substitutes
      3.5.5 Threat of New Entrants
      3.5.6 Competitive Rivalry
3.6 Market Analysis of Major Drugs and Vaccines for Hospital Acquired Pneumonia
      3.6.1 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
 
Chapter 4 Hospital Acquired Pneumonia, Pipeline Analysis
4.1 Introduction
4.2 Late Stage (Phase III)
      4.2.1 Tedizolid phosphate
               4.2.1.1 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD million)
      4.2.2 Ceftolozane/Tazobactam
              4.2.2.1 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
      4.2.3 Ceftazidime/Avibactum
              4.2.3.1 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
      4.2.4 Amikacin Inhale
              4.2.4.1 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
      4.2.5 Plazomicin
              4.2.5.1 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
      4.2.6 Synflorix Vaccine
              4.2.6.1 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
4.3 Early Stage (Phase I and II)
      4.3.1 BAL30072
      4.3.2 MEDI4893
      4.3.3 AR-301 or KBSA301
      4.3.4 AR-101 (or KBPA101) and AR-104 (or KBPA104)
      4.3.5 AR-201 (or KBRV201)
      4.3.6 AR-401 (or KBAB401)
      4.3.7 ME1100
      4.3.8 GSK 2189242A
      4.3.9 V114
      4.3.10 IC43
 
Chapter 5 Global Pipeline Review of Hospital Acquired Pneumonia Drugs Market, by Geography
5.1 Introduction
5.2 North America
5.3 Europe
5.4 Asia Pacific
5.5 Rest of the World
 
Chapter 6 Recommendations
6.1 Research and development for biological drugs
6.2 Mergers, acquisitions and strategic agreements
 
Chapter 7 Company Profiles
7.1 Achaogen, Inc.
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Aridis Pharmaceuticals
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 AstraZeneca plc
      7.3.1 Company Profile
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Cubist Pharmaceuticals, Inc.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
7.5 Meiji Seika Pharma Co. Ltd.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments
7.6 Merck & Co. Inc.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Sanofi
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 GlaxoSmithKline, Inc.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Valneva SE
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments

List of Tables
 
TABLE 1 Nosocomial Pneumonia Drugs and Vaccines, Market Snapshot
TABLE 2 Investigational Candidates for Nosocomial Pneumonia Treatment
TABLE 3 Prevalence of Hospital Acquired Infections in Developed and Developing Countries
TABLE 4 Event Impact Analysis, Hospital Acquired Pneumonia Market
 

List of Figures
 
FIG. 1 Hospital Acquired Pneumonia: Drug Pipeline
FIG. 2 Hospital Acquired Pneumonia Phase III Candidates, Market Share, 2020 (Value %)
FIG. 3 Value Chain Analysis
FIG. 4 Porter’s Five Forces Analysis: Global Hospital Acquired Pneumonia Market
FIG. 5 Revenue trend of major branded drugs and vaccines in nosocomial pneumonia market (USD Million)
FIG. 6 Global Tedizolid Phosphate Market Revenue, 2017 – 2020 (USD Million)
FIG. 7 Global Ceftolozane/Tazobactam Market Revenue, 2017 – 2020 (USD million)
FIG. 8 Global Ceftazidime/Avibactam Market Revenue, 2017 – 2020 (USD Million)
FIG. 9 Global Amikacin Inhale Market Revenue, 2016 – 2020 (USD Million)
FIG. 10 Global Plazomicin Market Revenue, 2017 – 2020 (USD Million)
FIG. 11 Global Synflorix Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 AstraZeneca PLC: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 13 Cubist Pharmaceuticals, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 14 Meiji Holdings, Co. Ltd., Pharmaceutical Segment.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 15 Merck & Co. Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 16 Sanofi: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 GlaxoSmithKline, Inc.: Annual Revenue, 2011 – 2013 (USD Million)